Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Supernus Pharmaceuticals (SUPN) Acquisitions (2020)

Supernus Pharmaceuticals has reported Acquisitions over the past 1 years, most recently at $1.3 million for Q4 2020.

Quarterly Acquisitions changed N/A to $1.3 million in Q4 2020 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Sep 2022, changed 0.0% year-over-year, with the annual reading at $293.1 million for FY2025, N/A changed from the prior year.
Acquisitions was $1.3 million for Q4 2020 at Supernus Pharmaceuticals.
Over five years, Acquisitions peaked at $1.3 million in Q4 2020 and troughed at $1.3 million in Q4 2020.